NASDAQ · Drug Manufacturers - Specialty & Generic

Aytu BioPharma, Inc. (AYTU) Stock

$2.03 -1.22% NASDAQ: AYTU Healthcare

Valuation

MetricValue
Price$2.03
Market Cap$21.73M
P/E Ratio-1.51
P/B Ratio0.72
P/S Ratio0.39
EPS (TTM)$-2.16
52-Week High$3.07
52-Week Low$1.80
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-52.89%
ROA-13.57%
ROCE-16.52%
Gross Margin-12.12%
Operating Margin-12.12%
Net Margin-24.76%
Debt/Equity0.51
Current Ratio1.25

Annual Financials (USD)

Metric20222023202420252026
Revenue$97.0M$107.0M$65.0M$66.0M$58.0M
Operating Profit$-110.0M$-17.0M$-2.0M$-8.0M$-8.0M
Net Profit$-109.0M$-17.0M$-16.0M$-14.0M$-14.0M
EPS$-74.01$-5.11$-2.86$-2.16$-1.16
Op Margin-113.7%-15.9%-2.4%-11.8%-14.4%

Balance Sheet (USD)

Metric20222023202420252026
Total Assets$138.0M$138.0M$119.0M$124.0M$105.0M
Total Liabilities$93.0M$98.0M$91.0M$105.0M$70.0M
Cash$19.0M$23.0M$20.0M$31.0M$26.0M
Borrowings$18.0M$30.0M$16.0M$23.0M$18.0M

Latest News

New Strong Sell Stocks for July 20th Zacks · Jul 20, 2026 New Strong Sell Stocks for July 16th Zacks · Jul 16, 2026 Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026 ACCESS Newswire · Jun 1, 2026 Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 ACCESS Newswire · May 18, 2026 Aytu BioPharma, Inc. Q3 2026 Earnings Call Summary Moby · May 14, 2026

Cash Flow (USD)

Metric20222023202420252026
Operating Cash Flow$-29.0M$-5.0M$-1.0M$-2.0M$3.0M
Investing Cash Flow$-3.0M$0$-1.0M$-6.0M$0
Financing Cash Flow$-5.0M$-4.0M$-3.0M$-6.0M$0
Net Cash Flow$-31.0M$4.0M$-3.0M$11.0M$-5.0M
Free Cash Flow$-29.0M$-5.0M$-2.0M$-5.0M$3.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.03
EV / EBITDA-1.65
FCF Yield14.64%
Quick Ratio1.00
Interest Coverage-7.36
Return 1Y2.30%
Return 3Y18.72%
Return 5Y-97.38%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADAPAdaptimmune Therapeutics plc $0.05 -3.00% -0.16 $75.16M 0.00%
ALURAllurion Technologies Inc. $4.72 -14.27% -0.08 $4.72M 0.00%
ANLAdlai Nortye Ltd. $13.26 +2.00% -8.19 $703.84M 0.00%
BFRIBiofrontera Inc. $0.97 +5.72% -1.69 $12.44M 0.00%
EKSOEkso Bionics Holdings, Inc. $15.90 -9.86% -2.95 $38.57M 0.00%

About Aytu BioPharma, Inc.

Aytu BioPharma, Inc. is led by CEO Joshua R. Disbrow, employs 102 people, headquartered in US, publicly traded since 2008.

Aytu BioPharma, Inc. (AYTU) stock trades at $2.03 with a market capitalization of $21.73M. The stock is valued at a price-to-earnings (P/E) ratio of -1.51, price-to-book of 0.72, price-to-sales of 0.39. Over the past 52 weeks the stock has ranged between $1.80 and $3.07, and currently trades 33.9% below its 52-week high.

On profitability, Aytu BioPharma, Inc. generates a return on equity (ROE) of -52.89%, return on capital employed of -16.52%, an operating margin of -12.12%, a net profit margin of -24.76%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides